Search research articles
Contact Us
Filters
Showing results (201-210 of 250) with videos related to
Page
of 25
Sort By:
The European Respiratory Journal
|
December 11, 2012
Prevalence and prognosis of unclassifiable interstitial lung disease
Christopher J Ryerson, Thomas H Urbania, Luca Richeldi, et al.
Respiratory Research
|
November 22, 2012
Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis
Seung-Ick Cha, Christopher J Ryerson, Joyce S Lee, et al.
The Lancet. Respiratory Medicine
|
April 20, 2015
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials
Michael T Durheim, Harold R Collard, Rhonda S Roberts, et al.
Annals of the American Thoracic Society
|
August 29, 2014
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward
Eric S White, Kevin K Brown, Harold R Collard, et al.
Respiratory Medicine
|
August 26, 2015
Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria
Deborah Assayag, Eunice J Kim, Brett M Elicker, et al.
Chest
|
November 7, 2016
Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis
Julie Morisset, Kerri A Johannson, Eric Vittinghoff, et al.
Chest
|
February 9, 2013
Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis
Joshua J Mooney, Brett M Elicker, Thomas H Urbania, et al.
The Lancet. Respiratory Medicine
|
August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Margaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
BMJ Open Respiratory Research
|
October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
Kevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Plos One
|
July 1, 2016
miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis
Supparerk Disayabutr, Eun Kyung Kim, Seung-Ick Cha, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 250) with videos related to
Sort By:
Page
of 25
The European Respiratory Journal
|
December 11, 2012
Prevalence and prognosis of unclassifiable interstitial lung disease
Christopher J Ryerson, Thomas H Urbania, Luca Richeldi, et al.
Respiratory Research
|
November 22, 2012
Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis
Seung-Ick Cha, Christopher J Ryerson, Joyce S Lee, et al.
The Lancet. Respiratory Medicine
|
April 20, 2015
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials
Michael T Durheim, Harold R Collard, Rhonda S Roberts, et al.
Annals of the American Thoracic Society
|
August 29, 2014
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward
Eric S White, Kevin K Brown, Harold R Collard, et al.
Respiratory Medicine
|
August 26, 2015
Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria
Deborah Assayag, Eunice J Kim, Brett M Elicker, et al.
Chest
|
November 7, 2016
Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis
Julie Morisset, Kerri A Johannson, Eric Vittinghoff, et al.
Chest
|
February 9, 2013
Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis
Joshua J Mooney, Brett M Elicker, Thomas H Urbania, et al.
The Lancet. Respiratory Medicine
|
August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Margaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
BMJ Open Respiratory Research
|
October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
Kevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Plos One
|
July 1, 2016
miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis
Supparerk Disayabutr, Eun Kyung Kim, Seung-Ick Cha, et al.
Page
of 25